1
2
3
We don't have analytics for this instrument yet. You can contribute!
Please log in and be the first author to write an article about this instrument!
Deciphera Pharmaceuticals, Inc. (NASDAQ)
Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing medicines to improve the lives of cancer patients in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 in combination with RTK/RAS/MAP kinase signaling pathway inhibition to treat RAS/RAF mutant cancers. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.
Trading schedule (UTC)
Open Now
Closed Now
Closes on
Opening on
at
-
This shows the opening hours in your local time zone
(UTC)
| Ticker | DCPH |
| Contract value | 100 shares |
| Maximum leverage | 1:5 |
Swaps history
| Date | Short Swap (%) | Long Swap (%) | No data |
|---|
| Minimum transaction volume | 0.01 lot |
| Maximum transaction volume | 100 lots |
| Hedging margin | 50% |
